A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma

NCT07497373 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Glioblastoma Multiforme(GBM)

Interventions

BIOLOGICAL: JL15003 Injection

Sponsor

Jecho Biopharmaceuticals Co., Ltd.